(Circulation. 1995;91:1952-1958.)
© 1995 American Heart Association, Inc.
Articles |
Association Between Increased Estrogen Status and Increased Fibrinolytic Potential in the Framingham Offspring Study
From the Institute for Prevention of Cardiovascular Disease, Cardiovascular Division, Deaconess Hospital, and Harvard Medical School, Boston, Mass (O.C.E.G., M.A.M., P.S., I.L., T.M., P.X., F.W., J.E.M., G.H.T.), and the Framingham Heart Study, Framingham, Mass (P.W.F.W., D.L.).
Correspondence to Geoffrey H. Tofler, MD, Institute for Prevention of Cardiovascular Disease, Deaconess Hospital, One Autumn St, 5th Floor, Boston, MA 02215.
Background Although extensive evidence indicates that estrogen is responsible for the markedly decreased cardiovascular risk of premenopausal women, the mechanism through which estrogen might exert its protective effect has not been adequately explained. Since thrombosis is now recognized to play an important role in the onset of cardiovascular disease, we investigated the relation between estrogen status and fibrinolytic potential, a determinant of thrombotic risk.
Methods and Results We determined levels of plasminogen activator inhibitor (PAI-1) antigen and tissue plasminogen activator (TPA) antigen in 1431 subjects from the Framingham Offspring Study. Fibrinolytic potential was compared between subjects with high estrogen status (premenopausal women and postmenopausal women receiving hormone replacement therapy) and low estrogen status (men and postmenopausal women not receiving hormone replacement therapy). In all comparisons, subjects with high estrogen status had greater fibrinolytic potential (lower PAI-1 levels) than subjects with low estrogen status. First, postmenopausal women receiving estrogen replacement therapy had lower levels of PAI-1 than those not receiving therapy (13.0±0.5 versus 19.5±1.0 ng/mL, P<.001). Second, premenopausal women had lower levels of PAI-1 than men of a similar age (14.8±0.6 versus 20.3±0.8 ng/mL, P<.001); this sex difference diminished when postmenopausal women not receiving hormone replacement therapy were compared with men of a similar age (19.6±0.7 versus 21.1±0.7 ng/mL, P=.089). Third, premenopausal women had markedly lower levels of PAI-1 antigen than postmenopausal women not receiving estrogen therapy (14.8±0.6 versus 19.5±1.0 ng/mL, P<.001). The between-group differences observed for TPA antigen were similar to those for PAI-1 antigen.
Conclusions Each of these comparisons indicates that the cardioprotective effect of estrogen may be mediated, in part, by an increase in fibrinolytic potential. These findings might provide at least a partial explanation for the protection against cardiovascular disease experienced by premenopausal women, and the loss of that protection following menopause.
Key Words: hormones • fibrinolysis • cardiovascular diseases
This article has been cited by other articles:
 |
|
 |
|
  M.S.V. Elkind, S. Prabhakaran, J. Pittman, W. Koroshetz, M. Jacoby, K. C. Johnston, and for the GAIN Americas Investigators Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke Neurology, March 13, 2007; 68(11): 842 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Bushnell, P. Hurn, C. Colton, V. M. Miller, G. del Zoppo, M. S.V. Elkind, B. Stern, D. Herrington, G. Ford-Lynch, P. Gorelick, et al. Advancing the Study of Stroke in Women: Summary and Recommendations for Future Research From an NINDS-Sponsored Multidisciplinary Working Group Stroke, September 1, 2006; 37(9): 2387 - 2399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh and B.-K. Yoon Controversies regarding hormone therapy: Insights from inflammation and hemostasis Cardiovasc Res, April 1, 2006; 70(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reimann, J. Dierkes, A. Carlsohn, D. Talbot, M. Ferrari, J. Hallund, W. L. Hall, K. Vafeiadou, U. Huebner, F. Branca, et al. Consumption of Soy Isoflavones Does Not Affect Plasma Total Homocysteine or Asymmetric Dimethylarginine Concentrations in Healthy Postmenopausal Women J. Nutr., January 1, 2006; 136(1): 100 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Sowers, K. A. Matthews, M. Jannausch, J. F. Randolph, D. McConnell, K. Sutton-Tyrrell, R. Little, B. Lasley, and R. Pasternak Hemostatic Factors and Estrogen during the Menopausal Transition J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 5942 - 5948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jayachandran, A. Sanzo, W. G. Owen, and V. M. Miller Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1908 - H1916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Savitz, G. Schlaug, L. Caplan, and M. Selim Arterial Occlusive Lesions Recanalize More Frequently in Women Than in Men After Intravenous Tissue Plasminogen Activator Administration for Acute Stroke Stroke, July 1, 2005; 36(7): 1447 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Szymanski, C. M. Kessler, and B. Fernhall Relationship of physical fitness, hormone replacement therapy, and hemostatic risk factors in postmenopausal women J Appl Physiol, April 1, 2005; 98(4): 1341 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-G. V. Giardina, H. J. Chen, R. R. Sciacca, and L. E. Rabbani Dynamic Variability of Hemostatic and Fibrinolytic Factors in Young Women J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6179 - 6184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Pradhan, A. Z. LaCroix, R. D. Langer, M. Trevisan, C. E. Lewis, J. A. Hsia, A. Oberman, J. M. Kotchen, and P. M Ridker Tissue Plasminogen Activator Antigen and D-Dimer as Markers for Atherothrombotic Risk Among Healthy Postmenopausal Women Circulation, July 20, 2004; 110(3): 292 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Kannel and D. Levy Menopause, Hormones, and Cardiovascular Vulnerability in Women Arch Intern Med, March 8, 2004; 164(5): 479 - 481. [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Ghali, H. J. Krause-Steinrauf, K. F. Adams Jr, S. S. Khan, Y. D. Rosenberg, C. W. Yancy Jr, J. B. Young, S. Goldman, M. A. Peberdy, and J. Lindenfeld Gender differences in advanced heart failure: insights from the BEST study J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2128 - 2134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sowers, C. Derby, M. L. Jannausch, J. I. Torrens, and R. Pasternak Insulin Resistance, Hemostatic Factors, and Hormone Interactions in Pre- and Perimenopausal Women: SWAN J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4904 - 4910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Carr The Emergence of the Metabolic Syndrome with Menopause J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2404 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Rabbani, N. A. Seminario, R. R. Sciacca, H. J. Chen, and E.-G. V. Giardina Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1991 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Stangl, G. Baumann, and K. Stangl Coronary atherogenic risk factors in women Eur. Heart J., November 2, 2002; 23(22): 1738 - 1752. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hognert, B. Ghanoum, H. Gustafsson, I. Milsom, and K. Manhem Acute Effects of Transdermal 17{beta}-Estradiol on Hemostatic Variables after 24-hour Treatment Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 239 - 243. [Abstract] [PDF]
|
|
|
|
 |
|
 J. B. Braunstein, D. W. Kershner, P. Bray, G. Gerstenblith, S. P. Schulman, W. S. Post, and R. S. Blumenthal Interaction of Hemostatic Genetics With Hormone Therapy : New Insights To Explain Arterial Thrombosis in Postmenopausal Women Chest, March 1, 2002; 121(3): 906 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, S. Oparil, B. Imthurn, and E. K. Jackson Sex hormones and hypertension Cardiovasc Res, February 15, 2002; 53(3): 688 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Shlipak, B. G. Angeja, A. S. Go, P. D. Frederick, J. G. Canto, and D. Grady Hormone Therapy and In-Hospital Survival After Myocardial Infarction in Postmenopausal Women Circulation, November 6, 2001; 104(19): 2300 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Angeja, M. G. Shlipak, A. S. Go, S. C. Johnston, P. D. Frederick, J. G. Canto, H. V. Barron, D. Grady, and for the National Registry of Myocardial Infarction Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1297 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Viscoli, L. M. Brass, W. N. Kernan, P. M. Sarrel, S. Suissa, and R. I. Horwitz A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke N. Engl. J. Med., October 25, 2001; 345(17): 1243 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. P. Luyer, S. Khosla, W. G. Owen, and V. M. Miller Prospective Randomized Study of Effects of Unopposed Estrogen Replacement Therapy on Markers of Coagulation and Inflammation in Postmenopausal Women J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3629 - 3634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Minai, T. Matsumoto, H. Horie, N. Ohira, H. Takashima, H. Yokohama, and M. Kinoshita Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1565 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Dubey and E. K. Jackson Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms Am J Physiol Renal Physiol, March 1, 2001; 280(3): F365 - F388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Kohler and P. J. Grant Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease N. Engl. J. Med., June 15, 2000; 342(24): 1792 - 1801. [Full Text] [PDF]
|
|
|
|
|
|
J. A. McCrohon, S. Nakhla, W. Jessup, K. K. Stanley, and D. S. Celermajer Estrogen and Progesterone Reduce Lipid Accumulation in Human Monocyte-Derived Macrophages : A Sex-Specific Effect Circulation, December 7, 1999; 100(23): 2319 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. de Valk-de Roo, C. D.A. Stehouwer, P. Meijer, V. Mijatovic, C. Kluft, P. Kenemans, F. Cohen, S. Watts, and C. Netelenbos Both Raloxifene and Estrogen Reduce Major Cardiovascular Risk Factors in Healthy Postmenopausal Women : A 2-Year, Placebo-Controlled Study Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2993 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Abbasi, T. McLaughlin, C. Lamendola, I. Lipinska, G. Tofler, and G. M. Reaven Comparison of Plasminogen Activator Inhibitor-1 Concentration in Insulin-Resistant Versus Insulin-Sensitive Healthy Women Arterioscler. Thromb. Vasc. Biol., November 1, 1999; 19(11): 2818 - 2821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Anderson, B. M Smith, and C. S Washnock Cardiovascular and renal benefits of dry bean and soybean intake Am. J. Clinical Nutrition, September 1, 1999; 70(3): 464S - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lansink, M. Jong, M. Bijsterbosch, M. Bekkers, K. Toet, L. Havekes, J. Emeis, and T. Kooistra Increased Clearance Explains Lower Plasma Levels of Tissue-Type Plasminogen Activator by Estradiol: Evidence for Potently Enhanced Mannose Receptor Expression in Mice Blood, August 15, 1999; 94(4): 1330 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Mendelsohn and R. H. Karas The Protective Effects of Estrogen on the Cardiovascular System N. Engl. J. Med., June 10, 1999; 340(23): 1801 - 1811. [Full Text] [PDF]
|
|
|
|
|
|
M. Cesari and G. P. Rossi Plasminogen Activator Inhibitor Type 1 in Ischemic Cardiomyopathy Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1378 - 1386. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oparil Hormones and Vasoprotection Hypertension, January 1, 1999; 33(1): 170 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Giltay, J. M. H. Elbers, L. J. G. Gooren, J. J. Emeis, T. Kooistra, H. Asscheman, and C. D. A. Stehouwer Visceral Fat Accumulation Is an Important Determinant of PAI-1 Levels in Young, Nonobese Men and Women : Modulation by Cross-Sex Hormone Administration Arterioscler. Thromb. Vasc. Biol., November 1, 1998; 18(11): 1716 - 1722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Pankow, A. R. Folsom, M. A. Province, D. C. Rao, R. R. Williams, J. Eckfeldt, and T. A. Sellers Segregation Analysis of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in the NHLBI Family Heart Study Arterioscler. Thromb. Vasc. Biol., October 1, 1998; 18(10): 1559 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O C E Gebara, M A Mittleman, B W Walsh, I Lipinska, F K Welty, G Bellotti, J E Muller, F K Sacks, and G H Tofler Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia Heart, September 1, 1998; 80(3): 235 - 239. [Abstract] [Full Text]
|
|
|
|
|
|
M. Margaglione, G. Cappucci, M. d'Addedda, D. Colaizzo, N. Giuliani, G. Vecchione, G. Mascolo, E. Grandone, and G. Di Minno PAI-1 Plasma Levels in a General Population Without Clinical Evidence of Atherosclerosis : Relation to Environmental and Genetic Determinants Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 562 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Henry, D.A. Tregouet, M.C. Alessi, M.F. Aillaud, S. Visvikis, G. Siest, L. Tiret, and I. Juhan-Vague Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations : A Family Study With Part of the Stanislas Cohort Arterioscler. Thromb. Vasc. Biol., January 1, 1998; 18(1): 84 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Scarabin, M. Alhenc-Gelas, G. Plu-Bureau, P. Taisne, R. Agher, and M. Aiach Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women : A Randomized Controlled Trial Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3071 - 3078. [Abstract] [Full Text]
|
|
|
|
|
|
D.-K. Kim, J.-W. Kim, S. Kim, H.-C. Gwon, J.-C. Ryu, J.-E. Huh, J.-A Choo, Y. Choi, C.-H. Rhee, and W.-R. Lee Polymorphism of Angiotensin Converting Enzyme Gene Is Associated With Circulating Levels of Plasminogen Activator Inhibitor-1 Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3242 - 3247. [Abstract] [Full Text]
|
|
|
|
|
|
K. K. Koh, R. Mincemoyer, M. N. Bui, G. Csako, F. Pucino, V. Guetta, M. Waclawiw, and R. O. Cannon Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal Women N. Engl. J. Med., March 6, 1997; 336(10): 683 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oparil, R. L. Levine, S.-J. Chen, J. Durand, and Y.F. Chen Sexually Dimorphic Response of the Balloon-Injured Rat Carotid Artery to Hormone Treatment Circulation, March 4, 1997; 95(5): 1301 - 1307. [Abstract] [Full Text]
|
|
|
|
|
|
H. Schunkert, A.H. J. Danser, H.-W. Hense, F. H.M. Derkx, S. Kurzinger, and G. A.J. Riegger Effects of Estrogen Replacement Therapy on the Renin-Angiotensin System in Postmenopausal Women Circulation, January 7, 1997; 95(1): 39 - 45. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Levine, S.-J. Chen, J. Durand, Y.-F. Chen, and S. Oparil Medroxyprogesterone Attenuates Estrogen-Mediated Inhibition of Neointima Formation After Balloon Injury of the Rat Carotid Artery Circulation, November 1, 1996; 94(9): 2221 - 2227. [Abstract] [Full Text]
|
|
|
|
|
|
P.-Y. Scarabin, A.-M. Vissac, J.-M. Kirzin, P. Bourgeat, J. Amiral, R. Agher, and L. Guize Population Correlates of Coagulation Factor VII: Importance of Age, Sex, and Menopausal Status as Determinants of Activated Factor VII Arterioscler. Thromb. Vasc. Biol., September 1, 1996; 16(9): 1170 - 1176. [Abstract] [Full Text]
|
|
|
|
|
|
C. D. Venkov, A. B. Rankin, and D. E. Vaughan Identification of Authentic Estrogen Receptor in Cultured Endothelial Cells: A Potential Mechanism for Steroid Hormone Regulation of Endothelial Function Circulation, August 15, 1996; 94(4): 727 - 733. [Abstract] [Full Text]
|
|
|
|
|
|
E. Shahar, A. R. Folsom, V. V. Salomaa, V. L. Stinson, P. G. McGovern, T. Shimakawa, L. E. Chambless, and K. K. Wu Relation of Hormone-Replacement Therapy to Measures of Plasma Fibrinolytic Activity Circulation, June 1, 1996; 93(11): 1970 - 1975. [Abstract] [Full Text]
|
|
|
|
|
|
V. Guetta and R. O. Cannon III Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women Circulation, May 15, 1996; 93(10): 1928 - 1937. [Full Text]
|
|
|
|
|
|
M. W. Mansfield, D. M. Heywood, and P. J. Grant Sex Differences in Coagulation and Fibrinolysis in White Subjects With Non–Insulin-Dependent Diabetes Mellitus Arterioscler. Thromb. Vasc. Biol., January 1, 1996; 16(1): 160 - 164. [Abstract] [Full Text]
|
|
|
|
|
|
C. H. Lundgren, S. L. Brown, T. K. Nordt, B. E. Sobel, and S. Fujii Elaboration of Type-1 Plasminogen Activator Inhibitor From Adipocytes : A Potential Pathogenetic Link Between Obesity and Cardiovascular Disease Circulation, January 1, 1996; 93(1): 106 - 110. [Abstract] [Full Text]
|
|
|
|
 |
|
 Estrogen Linked to Clot-Dissolving Activity Journal Watch Cardiology, June 1, 1995; 1995(601): 16 - 16. [Full Text]
|
|
|
|
|
|
D. Pratico and G. A. FitzGerald Testosterone and Thromboxane : Of Muscles, Mice, and Men Circulation, June 1, 1995; 91(11): 2694 - 2698. [Full Text]
|
|
|
|
 |
|
 ESTROGEN LINKED TO INCREASED CLOT-DISSOLVING ACTIVITY Journal Watch (General), April 11, 1995; 1995(411): 6 - 6. [Full Text]
|
|